Kanta Subbarao

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Scientific barriers to developing vaccines against avian influenza viruses
    Kanta Subbarao
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Immunol 7:267-78. 2007
  2. pmc Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice
    Kanta Subbarao
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 78:3572-7. 2004
  3. pmc The prospects and challenges of universal vaccines for influenza
    Kanta Subbarao
    National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health, Bethesda, MD, USA
    Trends Microbiol 21:350-8. 2013
  4. ncbi request reprint Is there an ideal animal model for SARS?
    Kanta Subbarao
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, MSC 8007, Bethesda, MD 20892, USA
    Trends Microbiol 14:299-303. 2006
  5. pmc H5N1 viruses and vaccines
    Kanta Subbarao
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States of America
    PLoS Pathog 3:e40. 2007
  6. pmc A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys
    Ji Young Min
    LID, NIAID, NIH, Bethesda, MD 20892, USA
    J Virol 84:11950-60. 2010
  7. pmc Evaluation of live attenuated influenza a virus h6 vaccines in mice and ferrets
    Zhongying Chen
    Laboratory of Infectious Diseases, NIAID, NIH, Bldg 33 Room 3E13C 1, 33 North Dr, MSC 3203, Bethesda, MD 20892, USA
    J Virol 83:65-72. 2009
  8. pmc Animal models and vaccines for SARS-CoV infection
    Anjeanette Roberts
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD, United States
    Virus Res 133:20-32. 2008
  9. pmc A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters
    Elaine W Lamirande
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA
    J Virol 82:7721-4. 2008
  10. pmc Avian influenza h6 viruses productively infect and cause illness in mice and ferrets
    Laura Gillim-Ross
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland 20892, USA
    J Virol 82:10854-63. 2008

Detail Information

Publications91

  1. ncbi request reprint Scientific barriers to developing vaccines against avian influenza viruses
    Kanta Subbarao
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Immunol 7:267-78. 2007
    ....
  2. pmc Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice
    Kanta Subbarao
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 78:3572-7. 2004
    ..Thus, antibodies, acting alone, can prevent replication of the SARS coronavirus in the lung, a promising observation for the development of vaccines, immunotherapy, and immunoprophylaxis regimens...
  3. pmc The prospects and challenges of universal vaccines for influenza
    Kanta Subbarao
    National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health, Bethesda, MD, USA
    Trends Microbiol 21:350-8. 2013
    ..Several recent scientific advances have generated renewed enthusiasm and hope for universal vaccines that will induce broad protection from a range of influenza viruses. ..
  4. ncbi request reprint Is there an ideal animal model for SARS?
    Kanta Subbarao
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, MSC 8007, Bethesda, MD 20892, USA
    Trends Microbiol 14:299-303. 2006
    ..Here, we suggest aspects of an ideal animal model for studies of SARS pathogenesis and vaccine development and present our assessment of the strengths and limitations of the current animal models for SARS...
  5. pmc H5N1 viruses and vaccines
    Kanta Subbarao
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States of America
    PLoS Pathog 3:e40. 2007
  6. pmc A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys
    Ji Young Min
    LID, NIAID, NIH, Bethesda, MD 20892, USA
    J Virol 84:11950-60. 2010
    ..The safety, immunogenicity, and efficacy of the H7N7 NL/03 ca vaccine virus in mice, ferrets, and AGMs support the evaluation of this vaccine virus in phase I clinical trials...
  7. pmc Evaluation of live attenuated influenza a virus h6 vaccines in mice and ferrets
    Zhongying Chen
    Laboratory of Infectious Diseases, NIAID, NIH, Bldg 33 Room 3E13C 1, 33 North Dr, MSC 3203, Bethesda, MD 20892, USA
    J Virol 83:65-72. 2009
    ..These data support the rationale for further evaluating the A/teal/HK/W312/97 ca vaccine in humans...
  8. pmc Animal models and vaccines for SARS-CoV infection
    Anjeanette Roberts
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD, United States
    Virus Res 133:20-32. 2008
    ....
  9. pmc A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters
    Elaine W Lamirande
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA
    J Virol 82:7721-4. 2008
    ..Despite being attenuated in replication in the respiratory tract, rSARS-CoV-DeltaE is an immunogenic and efficacious vaccine in hamsters...
  10. pmc Avian influenza h6 viruses productively infect and cause illness in mice and ferrets
    Laura Gillim-Ross
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland 20892, USA
    J Virol 82:10854-63. 2008
    ..However, we have identified an H6 virus that induces protective immunity against viruses in the North American and Eurasian lineages...
  11. pmc A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets
    Tomy Joseph
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA
    Virology 378:123-32. 2008
    ..The safety, immunogenicity, and efficacy of this vaccine in mice and ferrets support the evaluation of this vaccine in clinical trials...
  12. ncbi request reprint Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS
    Alexander Bukreyev
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet 363:2122-7. 2004
    ..We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS- coronavirus transmission and disease...
  13. ncbi request reprint Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys
    Josephine McAuliffe
    Laboratory of Infectious Diseases, NIAID, Bethesda, MD 20892, USA
    Virology 330:8-15. 2004
    ....
  14. pmc Evaluation of replication, immunogenicity and protective efficacy of a live attenuated cold-adapted pandemic H1N1 influenza virus vaccine in non-human primates
    Kobporn Boonnak
    Emerging Respiratory Viruses Section, Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892 3203, United States
    Vaccine 30:5603-10. 2012
    ....
  15. ncbi request reprint Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters
    Anjeanette Roberts
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 193:685-92. 2006
    ....
  16. pmc Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets
    Grace L Chen
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 203:930-6. 2011
    ....
  17. pmc The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus
    Amorsolo L Suguitan
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rm 3E13C 1, 33 North Drive, MSC 3203, Bethesda, MD 20892 3203, USA
    Virology 395:280-8. 2009
    ....
  18. ncbi request reprint Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein
    Himani Bisht
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 4 Center Drive, Bethesda, MD 20892 0445, USA
    Virology 334:160-5. 2005
    ..However, the best results were obtained with QS21 and protein, which provided the highest antibody as well as complete protection of the upper and lower respiratory tract...
  19. pmc Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model
    Tomy Joseph
    Laboratory of Infectious Diseases, NIAID, NIH, Bldg 33, Room 3E13C 1, 33 North Dr, MSC 3203, Bethesda, MD 20892, USA
    J Virol 81:10558-66. 2007
    ..The mouse model can be used for the preclinical evaluation of these vaccines against H7 subtype viruses...
  20. pmc Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine
    Anjeanette Roberts
    Laboratory of Infectious Diseases, NIAID, National Institutes of Health NIH, Bethesda, Maryland 20892, USA
    Viral Immunol 23:509-19. 2010
    ..Enhanced disease was not observed in the lungs or liver of hamsters following SARS-CoV challenge, regardless of the level of serum neutralizing antibodies...
  21. pmc Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity
    Ursula J Buchholz
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    Proc Natl Acad Sci U S A 101:9804-9. 2004
    ....
  22. pmc Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets
    Grace L Chen
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA
    Virology 398:109-14. 2010
    ..The AA ca vaccine is safe, immunogenic, and efficacious against homologous and heterologous challenge in mice and ferrets, supporting the evaluation of this vaccine in clinical trials...
  23. pmc Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV)
    Leatrice N Vogel
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA
    Vaccine 25:2173-9. 2007
    ..This study validates the utility of the aged BALB/c mouse model for evaluation of the efficacy of vaccines and immunoprophylaxis...
  24. pmc Replication and immunogenicity of swine, equine, and avian h3 subtype influenza viruses in mice and ferrets
    Mariana Baz
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA
    J Virol 87:6901-10. 2013
    ..We selected an equine and an avian H3 influenza virus for further development as vaccines...
  25. pmc Evaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets
    Grace L Chen
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland 20892 3203, USA
    J Virol 84:7695-702. 2010
    ..These data suggested that these three viruses may be suitable candidates for development as live attenuated H2 pandemic influenza virus vaccines...
  26. doi request reprint The mouse model for influenza
    Yumiko Matsuoka
    NIAID, NIH, Laboratory of Infectious Diseases, Bethesda, Maryland, USA
    Curr Protoc Microbiol . 2009
    ..Although they are not discussed in detail in this unit, hamsters, guinea pigs, cotton rats (Sigmodon), and rats (Rattus) have also been used for influenza research...
  27. pmc Antigen-activated dendritic cells ameliorate influenza A infections
    Kobporn Boonnak
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892 3203, USA
    J Clin Invest 123:2850-61. 2013
    ..This approach shows promise as an adjunct to antiviral treatment of influenza virus infections. ..
  28. pmc Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection
    Jun Chen
    Laboratory of Infectious Diseases, National Institute for Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892 3203, USA
    J Virol 84:1289-301. 2010
    ..Our findings provide new insights into the pathogenesis of SARS, demonstrating the important role of CD4(+) but not CD8(+) T cells in primary SARS-CoV infection in this model...
  29. doi request reprint Classical swine H1N1 influenza viruses confer cross protection from swine-origin 2009 pandemic H1N1 influenza virus infection in mice and ferrets
    Ji Young Min
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases NIH, Bethesda, MD 20892, USA
    Virology 408:128-33. 2010
    ..The data suggest that prior exposure to antigenically related H1N1 viruses of swine-origin provide some protective immunity against the 2009 pandemic H1N1 virus...
  30. pmc Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters
    Anjeanette Roberts
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Disease, Bethesda, Maryland 20892, USA
    J Virol 79:503-11. 2005
    ..The hamster, therefore, is superior to the mouse as a model for the evaluation of antiviral agents and candidate vaccines against SARS CoV replication...
  31. pmc Receptor specificity does not affect replication or virulence of the 2009 pandemic H1N1 influenza virus in mice and ferrets
    Seema S Lakdawala
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 446:349-56. 2013
    ....
  32. pmc The multibasic cleavage site of the hemagglutinin of highly pathogenic A/Vietnam/1203/2004 (H5N1) avian influenza virus acts as a virulence factor in a host-specific manner in mammals
    Amorsolo L Suguitan
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:2706-14. 2012
    ..Thus, the contribution of H5 HA MBS to the virulence of the HPAI H5N1 virus varies among mammalian hosts and is most significant in mice and ferrets and less remarkable in nonhuman primates...
  33. pmc Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice
    Yuk Fai Lau
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA
    Virology 406:80-7. 2010
    ..The broad-spectrum protection provided by PIKA makes it an attractive option for prophylaxis from infection with influenza A viruses...
  34. ncbi request reprint The Immunobiology of SARS*
    Jun Chen
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland 20892, USA
    Annu Rev Immunol 25:443-72. 2007
    ..Innate immunity is important for viral clearance in the mouse model. Virus-specific neutralizing antibodies that develop during convalescence prevent reinfection in animal models...
  35. pmc Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research CBER, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS Med 6:e1000049. 2009
    ..Characterizing the B cell responses in convalescent individuals could help in the design of future vaccines and therapeutics...
  36. pmc Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
    Zhongyu Zhu
    Protein Interactions Group, Center for Cancer Research Nanobiology Program, SAIC Frederick, Inc, National Cancer Institute Frederick, National Institutes of Health, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 104:12123-8. 2007
    ..These antibodies exhibit cross-reactivity against isolates from the two SARS outbreaks and palm civets and could have potential applications for diagnosis, prophylaxis, and treatment of SARS-CoV infections...
  37. pmc Mammalian adaptation in the PB2 gene of avian H5N1 influenza virus
    Ji Young Min
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA
    J Virol 87:10884-8. 2013
    ..This mutation correlated with efficient replication of the virus in mice. ..
  38. pmc Eurasian-origin gene segments contribute to the transmissibility, aerosol release, and morphology of the 2009 pandemic H1N1 influenza virus
    Seema S Lakdawala
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 7:e1002443. 2011
    ..We have demonstrated that the viruses are released into exhaled air to varying degrees and a constellation of genes influences the transmissibility of the pH1N1 virus...
  39. pmc Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease
    Matthew Frieman
    Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA
    J Virol 86:884-97. 2012
    ..This panel of SARS-CoVs provides novel reagents that we have used to further our understanding of differential, age-related pathogenic mechanisms in mouse models of human disease...
  40. ncbi request reprint A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
    Zhi Yong Yang
    Vaccine Research Center, NIAID, National Institutes of Health, Building 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    Nature 428:561-4. 2004
    ..Gene-based vaccination for the SARS-CoV elicits effective immune responses that generate protective immunity in an animal model...
  41. pmc An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice
    Yuk Fai Lau
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland 20892, USA
    J Virol 84:8639-49. 2010
    ..These data suggest that TLR3 is important for the optimal performance of PIKA as an adjuvant. With its good safety profile and antigen-sparing effect, PIKA could be an attractive adjuvant for use in future pandemics...
  42. ncbi request reprint Animal models and antibody assays for evaluating candidate SARS vaccines: summary of a technical meeting 25-26 August 2005, London, UK
    Anjeanette Roberts
    National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
    Vaccine 24:7056-65. 2006
    ....
  43. pmc Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans
    Anjeanette Roberts
    LID, NIAID, NIH, 50 South Dr, Room 6351, MSC 8007, Bethesda, MD 20892, USA
    J Virol 79:5833-8. 2005
    ..We report here that viral replication in aged mice was associated with clinical illness and pneumonia, demonstrating an age-related susceptibility to SARS disease in animals that parallels the human experience...
  44. ncbi request reprint Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice
    William G Glass
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 173:4030-9. 2004
    ..In this species, proinflammatory chemokines may coordinate a rapid and highly effective innate antiviral response in the lung, but NK cells and adaptive cellular immunity are not required for viral clearance...
  45. pmc An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults
    Kawsar R Talaat
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Influenza Other Respir Viruses 7:66-73. 2013
    ..Live attenuated influenza vaccines (LAIV) against a variety of strains of pandemic potential are being developed and tested. We describe the results of an open-label phase I trial of a live attenuated H2N2 virus vaccine...
  46. ncbi request reprint Animal models for SARS
    Anjeanette Roberts
    NIAID, National Institutes of Health, Bethesda, Maryland 20892, USA
    Adv Exp Med Biol 581:463-71. 2006
  47. pmc pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN
    Zhi Yong Yang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 40, Room 4502, MSC 3005, 40 Convent Dr, Bethesda, MD 20892 3005, USA
    J Virol 78:5642-50. 2004
    ....
  48. pmc The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokines
    Yuk Fai Lau
    Laboratory of Infectious Diseases, NIAID, NIH, Bldg 33, Room 3E13C 1, 33 North Drive, MSC 3203, Bethesda, MD 20892 3203, USA
    J Virol 85:76-85. 2011
    ..Our results highlight the different requirements for inducing systemic and lung immunity that can be explored for the development of pulmonary immunity for protection against respiratory pathogens...
  49. pmc Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets
    Amorsolo L Suguitan
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Med 3:e360. 2006
    ....
  50. pmc The PB2 subunit of the influenza virus RNA polymerase affects virulence by interacting with the mitochondrial antiviral signaling protein and inhibiting expression of beta interferon
    Katy M Graef
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3203, USA
    J Virol 84:8433-45. 2010
    ..Overall this study implicates the PB2 protein in the regulation of host antiviral innate immune pathways and suggests an important role for the mitochondrial association of the PB2 protein in determining virulence...
  51. pmc The open reading frame 3a protein of severe acute respiratory syndrome-associated coronavirus promotes membrane rearrangement and cell death
    Eric C Freundt
    Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 84:1097-109. 2010
    ..These results establish an important role for ORF 3a in SARS-CoV-induced cell death, Golgi fragmentation, and the accumulation of intracellular vesicles...
  52. pmc Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine
    Grace L Chen
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 108:1140-5. 2011
    ..In summary, prior infection with a seasonal influenza virus or s-LAIV primed mice for a robust response to a single dose of p-LAIV that was associated with protection equivalent to two doses of the matched pandemic vaccine...
  53. doi request reprint The ferret model for influenza
    Yumiko Matsuoka
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA
    Curr Protoc Microbiol . 2009
    ..Although they are not discussed in detail in this unit, hamsters, guinea pigs, and both cotton rats (Sigmodon) and rats (Rattus) have also been used for influenza research...
  54. pmc The contribution of systemic and pulmonary immune effectors to vaccine-induced protection from H5N1 influenza virus infection
    Yuk Fai Lau
    Laboratory of Infectious Diseases, NIAID, NIH Bethesda, Maryland, USA
    J Virol 86:5089-98. 2012
    ..Understanding the requirements for effective induction and establishment of these protective immune effectors in the respiratory tract paves the way for a more rational and effective vaccine approach in the future...
  55. pmc A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice
    Anjeanette Roberts
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 3:e5. 2007
    ..This virus will be of value as a stringent challenge in evaluation of the efficacy of vaccines and antivirals...
  56. pmc Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice
    Himani Bisht
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:6641-6. 2004
    ..The attenuated nature of MVA and the ability of MVA/S to induce neutralizing antibody that protects mice support further development of this candidate vaccine...
  57. pmc The contribution of animal models to the understanding of the host range and virulence of influenza A viruses
    Christopher D O'Donnell
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA
    Microbes Infect 13:502-15. 2011
    ..The following review discusses the contribution of mice, ferrets, and non-human primates to the study of influenza virus host range and pathogenicity...
  58. ncbi request reprint Human infections with avian influenza viruses
    Tomy Joseph
    Laboratory of Infectious Diseases, NIAID, National Institutes of Health, Bethesda, Maryland, USA
    Md Med 6:30-2. 2005
    ....
  59. doi request reprint FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007
    Maryna Eichelberger
    US Food and Drug Administration, Center for Biologics Evaluation and Research Office of Vaccines Research and Review, Division of Viral Products, Bethesda, MD 20892, USA
    Vaccine 26:4299-303. 2008
    ....
  60. pmc Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus
    Christopher D O'Donnell
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:8625-33. 2012
    ..This provides a mechanistic understanding of the nature of serological cross-protection observed in people over 60 years of age during the 2009 H1N1 pandemic...
  61. ncbi request reprint Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV
    Miriam E R Darnell
    Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448, Bethesda, MD 20892, USA
    J Virol Methods 121:85-91. 2004
    ..We describe the kinetics of these efficient viral inactivation methods, which will allow research with SARS-CoV containing materials, that are rendered non-infectious, to be conducted at reduced safety levels...
  62. doi request reprint Live attenuated vaccines for pandemic influenza
    Grace L Chen
    Laboratory of Infectious Diseases, NIAID, NIH, Building 33, 3E 13C 2, 33 North Drive, MSC 3203, Bethesda, MD 20892 3203, USA
    Curr Top Microbiol Immunol 333:109-32. 2009
    ....
  63. pmc Emerging respiratory viruses: challenges and vaccine strategies
    Laura Gillim-Ross
    Laboratory of Infectious Diseases, National Insitute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Clin Microbiol Rev 19:614-36. 2006
    ....
  64. pmc Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses?
    Laura Gillim-Ross
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Med 4:e91. 2007
  65. ncbi request reprint Development of effective vaccines against pandemic influenza
    Kanta Subbarao
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Immunity 24:5-9. 2006
    ..A key strategy to protect humans against an influenza pandemic is the development of an effective vaccine. However, the development of effective pandemic vaccines poses both practical and immunological challenges...
  66. pmc Vaccines for pandemic influenza
    Catherine J Luke
    National Institutes of Health, Bethesda, Maryland 20892, USA
    Emerg Infect Dis 12:66-72. 2006
    ..Studies of such vaccines will also add to our understanding of the biology of avian influenza viruses and their behavior in mammalian hosts...
  67. pmc Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies
    Audray K Harris
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 110:4592-7. 2013
    ....
  68. pmc Influenza virus vaccines: lessons from the 2009 H1N1 pandemic
    Andrew J Broadbent
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA
    Curr Opin Virol 1:254-62. 2011
    ..Case-control studies demonstrated that monovalent 2009 H1N1 vaccines were effective in preventing infection with the 2009 H1N1 virus, but preliminary data suggests that it is important for individuals to be re-immunized annually...
  69. pmc Engineering H5N1 avian influenza viruses to study human adaptation
    David M Morens
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 486:335-40. 2012
    ....
  70. ncbi request reprint Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons
    Michael W Shaw
    National Microbiology Laboratory, Canadian Science Center for Human and Animal Health, Winnipeg, Manitoba, R3E 3R2, Canada
    Virology 303:1-8. 2002
    ....
  71. pmc DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice
    Suzanne L Epstein
    Food and Drug Administration, Rockville, Maryland 20852 1448, USA
    Emerg Infect Dis 8:796-801. 2002
    ..In the absence of antigenically matched hemagglutinin-based vaccines, DNA vaccination with conserved influenza genes may provide a useful first line of defense against a rapidly spreading pandemic virus...
  72. pmc Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model
    Taronna R Maines
    Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Proc Natl Acad Sci U S A 103:12121-6. 2006
    ..These results highlight the complexity of the genetic basis of influenza virus transmissibility and suggest that H5N1 viruses may require further adaptation to acquire this essential pandemic trait...
  73. pmc A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo
    Marta L DeDiego
    Department of Molecular and Cell Biology, Centro Nacional de Biotecnologia, CSIC, Darwin 3, Campus Universidad Autonoma, Cantoblanco, 28049 Madrid, Spain
    J Virol 81:1701-13. 2007
    ..Therefore, the SARS-CoV that lacks the E gene is attenuated in hamsters, might be a safer research tool, and may be a good candidate for the development of a live attenuated SARS-CoV vaccine...
  74. ncbi request reprint Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro
    Yiu Wing Kam
    HKU Pasteur Research Centre, 8 Sassoon Road, Hong Kong SAR, China
    Vaccine 25:729-40. 2007
    ..Altogether our results indicate that a recombinant trimeric S protein was able to elicit an efficacious protective immune response in vivo and warrant concern in the safety evaluation of a human vaccine against SARS-CoV...
  75. pmc Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins
    Erik Prentice
    Department of Microbiology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    J Virol 78:9977-86. 2004
    ..Further, the results demonstrate the ability of replicase antibodies to detect SARS-CoV-infected cells as early as 6 h postinfection and thus represent important tools for studies of SARS-CoV replication, inhibition, and diagnosis...
  76. pmc Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection
    Jennifer A Schwartz
    Department of Pathology, Yale University School of Medicine, 310 Cedar St LH 315, New Haven, CT 06520, USA
    Virology 366:166-73. 2007
    ..Our data indicate that these recombinants are promising vaccine candidates for pandemic influenza...
  77. pmc Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza
    Cameron P Simmons
    Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam
    PLoS Med 4:e178. 2007
    ..We generated neutralizing anti-H5N1 human monoclonal antibodies (mAbs) and tested their efficacy for prophylaxis and therapy in a murine model of infection...
  78. ncbi request reprint An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus
    Elisabetta Traggiai
    Institute for Research in Biomedicine, Via Vela 6, CH 6500 Belllinzona, Switzerland
    Nat Med 10:871-5. 2004
    ..These results show that it is possible to interrogate the memory repertoire of immune donors to rapidly and efficiently isolate neutralizing antibodies that have been selected in the course of natural infection...
  79. ncbi request reprint Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice
    Thomas C Greenough
    Department of Pediatrics, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 02130, USA
    J Infect Dis 191:507-14. 2005
    ..Human monoclonal antibodies (MAbs) that neutralize SARS-associated coronavirus (SARS-CoV) could provide protection for exposed individuals...
  80. pmc Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants
    Jianhua Sui
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, 44 Binney St, JFB 824, Boston, MA 02115, USA
    J Virol 79:5900-6. 2005
    ..Our study also cautions that for any prophylaxis strategy based on neutralizing antibody responses, whether by passive or active immunization, a genotyping monitor will be necessary for effective use...
  81. pmc Genomic analysis reveals age-dependent innate immune responses to severe acute respiratory syndrome coronavirus
    Tracey Baas
    Department of Microbiology, Box 358070, University of Washington, Seattle, WA 98195 8070, USA
    J Virol 82:9465-76. 2008
    ..We provide insight into gene expression profiles and molecular signatures underlying immunosenescence in the context of the host response to viral infection...
  82. ncbi request reprint Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine
    Sagar U Kapadia
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    Virology 340:174-82. 2005
    ..A VSV-vectored SARS vaccine could have significant advantages over other SARS vaccine candidates described to date...
  83. ncbi request reprint Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate
    Hualan Chen
    Influenza Branch, Mailstop G 16, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
    Vaccine 21:1974-9. 2003
    ..These results indicate that the high growth G9/PR8 reassortant has properties that are desirable in a vaccine seed virus and is suitable for evaluation in humans for use in the event of an H9 pandemic...
  84. pmc SARS vaccine protective in mice
    Konrad Stadler
    Emerg Infect Dis 11:1312-4. 2005
  85. ncbi request reprint Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine
    Rick A Bright
    Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Virology 308:270-8. 2003
    ....
  86. ncbi request reprint Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics
    Kanta Subbarao
    Influenza Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Virology 305:192-200. 2003
    ..This is the first successful attempt to develop an H5N1 vaccine seed virus resembling those used in currently licensed influenza A vaccines with properties that make it a promising candidate for further evaluation in humans...
  87. pmc Performance of rapid tests for detection of avian influenza A virus types H5N1 and H9N2
    Daniel P Fedorko
    J Clin Microbiol 44:1596-7. 2006
  88. ncbi request reprint Molecular epidemiology of influenza A(H3N2) virus reinfections
    Catherine B Smith
    Influenza Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Infect Dis 185:980-5. 2002
    ....
  89. ncbi request reprint Intercontinental circulation of human influenza A(H1N2) reassortant viruses during the 2001-2002 influenza season
    Xiyan Xu
    Influenza Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Infect Dis 186:1490-3. 2002
    ....
  90. ncbi request reprint Reassortment and evolution of current human influenza A and B viruses
    Xiyan Xu
    Influenza Branch, Centers for Disease Control and Prevention, Mail Stop G16, 1600 Clifton Road, NE, Atlanta, GA 30333, USA
    Virus Res 103:55-60. 2004
    ..On the other hand, widespread circulation of influenza B Victoria lineage viruses required inclusion of a strain from this lineage in influenza vaccines for the 2002-2003 season...
  91. ncbi request reprint Polygenic virulence factors involved in pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice
    Hualan Chen
    Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road, N E, MS G16, Atlanta, GA 30333, USA
    Virus Res 128:159-63. 2007
    ..Multiple genes are involved in virulence of Hong Kong H5N1 influenza A viruses for mice with the presence of lysine at aa627 in the PB2 gene exhibiting a significantly larger effect than the HA and NA genes...